Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 15/20 | 0.39 |
| ▸ | CD74 | P04233 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14144734 | 0.89 | BRD4 (0.46) | BRD4CREBBPCNR2 | |
| SCHEMBL4923461 | 0.87 | CNR2 (0.47) | BRD4CREBBPCNR2KMT2A | |
| SCHEMBL4926420 | 0.84 | BRD4 (0.41) | BRD4CREBBPCNR2KMT2A | |
| SCHEMBL14113974 | 0.84 | BRD4 (0.51) | BRD4CREBBPCNR2 | |
| SCHEMBL4923871 | 0.83 | CREBBP (0.64) | BRD4CREBBPCTSSSCN9A | |
| SCHEMBL4929940 | 0.82 | BRD4 (0.66) | BRD4CREBBPCNR2CTSSCD74 | |
| SCHEMBL4924516 | 0.82 | CNR2 (0.43) | BRD4CREBBPCNR2KMT2A | |
| SCHEMBL4921014 | 0.82 | CNR2 (0.44) | BRD4CREBBPCNR2 | |
| SCHEMBL4923915 | 0.81 | BRD4 (0.49) | BRD4CREBBPCNR2 | |
| SCHEMBL4914588 | 0.81 | BRD4 (0.50) | BRD4CREBBPCNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079316-A1 | TETRAHYDROQUINOLINONES, TETRAHYDRONAPHTHYRIDONES AND DERIVATIVES THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CARA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161340-A1 | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof | CNR1, CNR2, TRPV1 | BRD4 407/4885CREBBP 3109/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.